Lamotrigine monotherapy for newly diagnosed typical absence seizures in children
Gregory L Holmes1, L Matthew Frank, Raj D Sheth
1Neuroscience Center at Dartmouth, Dartmouth Medical School, Lebanon, NH, USA. Gregory.L.Holmes@dartmouth.edu
Insights
Lamotrigine monotherapy effectively controlled typical absence seizures in children, achieving significant seizure freedom rates. The treatment was well-tolerated, with most adverse events being mild.
Area of Science:
- Pediatric Neurology
- Epileptology
- Clinical Pharmacology
Background:
- Typical absence seizures are a common epilepsy syndrome in children.
- Effective monotherapy is crucial for managing pediatric epilepsy syndromes.
- Lamotrigine is an established antiepileptic drug with a broad spectrum of action.
Purpose of the Study:
- To assess lamotrigine's efficacy in achieving seizure freedom in newly diagnosed typical absence seizures in children.
- To evaluate the tolerability and safety profile of lamotrigine monotherapy.
- To examine the impact of lamotrigine on behavioral and psychosocial functioning.
Main Methods:
- A prospective study involving 54 children with newly diagnosed typical absence seizures.
- Lamotrigine was titrated over 20 weeks, with seizure control assessed via diaries, clinical hyperventilation, and EEG.
- Patients achieving seizure freedom entered a maintenance phase, with continued monitoring of seizure status and health outcomes.
Main Results:
- Seizure-free rates by the end of the escalation phase were 59% (diary) and 56% (HV/EEG).
- During maintenance, seizure freedom persisted in 78-89% of patients.
- The most common adverse events were headache and cough; health outcomes remained stable or improved.
Conclusions:
- Lamotrigine monotherapy is effective in achieving complete seizure freedom for a significant proportion of children with typical absence seizures.
- Lamotrigine demonstrated good tolerability in this pediatric population.
- The findings support lamotrigine as a viable treatment option for childhood absence epilepsy.
Purpose:
To evaluate the efficacy, tolerability, and effects on behavior and psychosocial functioning of lamotrigine monotherapy in children with newly diagnosed typical absence seizures.
Patients And Methods:
Children meeting enrollment criteria (n=54) received a confirmatory 24-h ambulatory electroencephalogram (EEG) and then entered a Escalation Phase of up to 20-weeks during which lamotrigine was titrated until seizures were controlled or maximum dose (10.2mg/kg) was reached. Seizure freedom was assessed by diary review and clinic hyperventilation (clinic HV) and then confirmed by EEG with hyperventilation (HV/EEG). Patients who maintained seizure freedom for two consecutive weekly visits were entered into the Maintenance Phase (n=30). Diary, clinic HV, and HV/EEG data were supplemented with 24-h ambulatory EEG at baseline and the ends of the Escalation and Maintenance Phases. Health outcome assessments were completed at screening and at the end of the Maintenance Phase.
Results:
By the end of the Escalation Phase, seizure-free rates (responders) were 59% by seizure diary (n=51), 56% by HV/EEG (n=54) (primary endpoint), and 49% by 24-h ambulatory EEG (n=49). During the Maintenance Phase, 89% (week 24) and 86% (week 32) remained seizure free by diary (n=28), 78% by clinic HV (n=27), and 81% by 24-h ambulatory EEG (n=26). Seizure freedom was first observed beginning at the fifth week of the Escalation Phase. The most frequent adverse events were headache and cough. Health outcome scores were either improved or unchanged at the end of the Maintenance Phase.
Conclusions:
Lamotrigine monotherapy results in complete seizure freedom in a substantial number of children with typical absence seizures. Lamotrigine was well tolerated in this study.
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...